METTL3, the core methyltransferase involved in m6A modification, has been reported to play significant roles in normal hematopoiesis and hematological malignancies including AML, acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), and lymphoma [14, 15]. Here, METTL3 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.